On August 31, GE HealthCare (NASDAQ:GEHC) announced that its Photonova Spectra photon-counting CT scanner had received CE Mark approval, opening the door to sales across Europe and other regions that recognize the certification. The clearance followed US FDA 510(k) clearance and Japanese regulatory approval in March 2026, meaning the machine cleared three major regulatory bodies within roughly five months.
A Machine Built For Speed
Photonova Spectra is built around GE HealthCare’s proprietary Deep Silicon detector technology, which the company says lets the scanner capture spectral information on every scan rather than only on request. The system rotates in 0.23 seconds and covers 80 millimeters per rotation, specs the company points to as enabling motion-free imaging even in complex cases. It processes up to 50 times more data than a conventional CT scanner, and it hands off to NVIDIA’s accelerated computing platform so the added detail does not slow down a radiology department’s workflow. GE HealthCare is pairing the launch with clinical research partnerships at UZ Brussel in Belgium and Rigshospitalet in Copenhagen, aimed at building out use cases in cardiology, oncology, and musculoskeletal imaging.
The bigger picture backs up the product story. In the quarter ended June 30, GE HealthCare posted record organic orders growth of 11.1%, alongside a book-to-bill ratio of 1.15 and a backlog of $23.9 billion. Revenue for the quarter reached $5.3 billion, up 5.7%, with the Advanced Imaging Solutions segment that Photonova Spectra sits inside growing organic revenue 5.0% and Pharmaceutical Diagnostics growing 14.6%. Management reaffirmed full-year guidance for organic revenue growth of 3.0% to 4.0% and adjusted earnings per share of $4.80 to $5.00, a sign it expects new products like this one to keep contributing.
One Segment Still Struggling
Not every part of the business is moving in the same direction. Patient Care Solutions, the segment covering patient monitoring and related equipment, saw revenue drop 13.3% in the quarter ended June 30, 2026, and swung to a segment EBIT loss of $26 million, a margin decline of 1,150 basis points from a year earlier. GE HealthCare said it is reviewing strategic options for that unit, language that leaves its future shape an open question. Company-wide, adjusted EBIT margin slipped 40 basis points to 14.2%, and management still expects roughly $250 million in inflation this year tied to memory chips, oil, and freight.
Diluted earnings per share of $1.24, up 16.5% from a year earlier, and net income of $561 million both included $129 million in refunds tied to tariffs imposed under the International Emergency Economic Powers Act, a benefit that will not repeat every quarter. Cash and cash equivalents fell to $2.1 billion by June 30, 2026, after the company put $2,293 million toward acquisitions in the first half of the year, and total debt outstanding stood at $10.1 billion. None of that stopped the company from buying back $200 million of stock in the quarter, but it does mean the balance sheet is carrying more of the load than the income statement alone suggests.
What The Numbers Say
59 hedge funds held GE HealthCare shares last quarter, down slightly from 60, a mild pullback rather than a stampede. Short interest sits at 4.37% of the float, pointing to some organized skepticism without a crowded short trade. The stock trades at a forward price-to-earnings ratio of 14.71 as of September 1, a multiple that hardly reflects the double-digit order growth the company just reported. That mix suggests that investors want more proof before rewarding the stock further.
Two Different Stories Ahead
Photonova Spectra gives GE HealthCare a genuine technology story, a scanner cleared in three major markets inside five months and already drawing academic research partners. But the same quarter that produced record orders also produced a shrinking Patient Care Solutions business and earnings padded by tariff refunds that will not repeat. The bull case needs Advanced Imaging Solutions and Pharmaceutical Diagnostics to keep growing fast enough to outrun that decline, while the bear case needs the strategic review of Patient Care Solutions to keep dragging or inflation to outpace the company’s ability to reprice.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
